@article{7c97a1560fde4733a140ed3a581fa8a0,
title = "Follow the data: Bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes",
keywords = "Bivalirudin, Coronary artery disease, Heparin, Percutaneous coronary intervention",
author = "Stone, {Gregg W.} and Roxana Mehran and Steg, {Philippe Gabriel}",
note = "Funding Information: Dr. Stone is a past consultant to Boston Scientific and the Eli Lilly-Daiichi Sankyo partnership. Dr. Mehran has received institutional research grants from The Medicines Company , Sanofi-Aventis , Bristol-Myers Squibb , AstraZeneca , and the Eli Lilly-Daiichi Sankyo partnership; and has served as a consultant to Boston Scientific, Abbott Vascular, AstraZeneca, Covidien, Regado Biosciences, Merck, Janssen, Maya Medical, CSL Behring, Claret, and The Medicines Company. Dr. Steg has received research grants from Sanofi and Servier (to INSERM U-1148); has received personal fees, including speaker and consulting fees, from Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen, Eli Lilly, Medtronic, Merck Sharpe Dohme, Novartis, Orexigen, Otsuka, Pfizer, Roche, The Medicines Company, Sanofi, Servier, and Vivus; and is a stockholder in Aterovax. ",
year = "2015",
month = jan,
day = "1",
doi = "10.1016/j.jcin.2014.10.004",
language = "English",
volume = "8",
pages = "225--227",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "1",
}